IN8bio Inc (INAB) concluded trading on Thursday at a closing price of $0.16, with 0.47 million shares of worth about $74675.84 changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -31.24% during that period and on April 17, 2025 the price saw a gain of about 2.09%. Currently the company’s common shares owned by public are about 72.48M shares, out of which, 64.72M shares are available for trading.
Stock saw a price change of 9.38% in past 5 days and over the past one month there was a price change of -31.79%. Year-to-date (YTD), INAB shares are showing a performance of -37.44% which decreased to -83.59% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.13 but also hit the highest price of $1.74 during that period. The average intraday trading volume for IN8bio Inc shares is 5.32 million. The stock is currently trading -8.16% below its 20-day simple moving average (SMA20), while that difference is down -29.20% for SMA50 and it goes to -56.84% lower than SMA200.
IN8bio Inc (NASDAQ: INAB) currently have 72.48M outstanding shares and institutions hold larger chunk of about 30.34% of that.
The stock has a current market capitalization of $13.08M and its 3Y-monthly beta is at 0.22. It has posted earnings per share of -$0.62 in the same period. It has Quick Ratio of 4.08 while making debt-to-equity ratio of 0.35. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for INAB, volatility over the week remained 9.09% while standing at 10.82% over the month.
Stock’s fiscal year EPS is expected to rise by 63.45% while it is estimated to decrease by -4.00% in next year. EPS is likely to grow at an annualized rate of 23.82% for next 5-years, compared to annual growth of -13.22% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Laidlaw on March 18, 2024 offering a Buy rating for the stock and assigned a target price of $7.50 to it. Coverage by H.C. Wainwright stated IN8bio Inc (INAB) stock as a Buy in their note to investors on August 30, 2022, suggesting a price target of $14 for the stock.
